Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

Cancer

Volumn 121, Issue 19, 2015, Pages 3435-3443

  Michaelson, M Dror ^a   McKay, Rana R ^b   Werner, Lillian ^b   Atkins, Michael B ^c   Van Allen, Eliezer M ^b   Olivier, Kara M ^a   Song, Jiaxi ^d   Signoretti, Sabina ^d   McDermott, David F ^e   Choueiri, Toni K ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

chemotherapy; poor risk; renal cell carcinoma; sarcomatoid; targeted; vascular endothelial growth factor (VEGF)

Indexed keywords

BIOLOGICAL MARKER; GEMCITABINE; SUNITINIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER RISK; CANCER SURVIVAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SARCOMATOID CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES;

EID: 84941935216     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29503     Document Type: Article

References (28)

1. de Peralta-Venturina M, Moch H, Amin M, et al., Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001; 25: 275-284.
2. Kyriakopoulos CE, Chittoria N, Choueiri TK, et al., Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer. 2015; 13: e79-e85.
3. Molina AM, Tickoo SK, Ishill N, et al., Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol. 2011; 34: 454-459.
4. Beuselinck B, Lerut E, Wolter P, et al., Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. Clin Genitourin Cancer. 2014; 12: e205-e214.
5. Voss MH, Bastos DA, Karlo CA, et al., Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol. 2014; 25: 663-668.
6. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J,. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530-2540.
7. Hudes G, Carducci M, Tomczak P, et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
8. Escudier B, Pluzanska A, Koralewski P, et al., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111.
9. Motzer RJ, Hutson TE, Tomczak P, et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
10. Motzer RJ, McCann L, Deen K,. Pazopanib versus sunitinib in renal cancer. N Engl J Med. 2013; 369: 1970.
11. Sternberg CN, Davis ID, Mardiak J, et al., Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
12. Buti S, Bersanelli M, Sikokis A, et al., Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs. 2013; 24: 535-554.
13. Dutcher JP, Nanus D,. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol. 2011; 28: 1530-1533.
14. Haas NB, Lin X, Manola J, et al., A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012; 29: 761-767.
15. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP,. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004; 101: 1545-1551.
16. Golshayan AR, George S, Heng DY, et al., Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009; 27: 235-241.
17. Michaelson MD, Zhu AX, Ryan DP, et al., Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer. 2013; 108: 1393-1401.
18. Bellmunt J, Trigo JM, Calvo E, et al., Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010; 11: 350-357.
19. Buti S, Lazzarelli S, Chiesa MD, et al., Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: an Italian Oncology Group for Clinical Research (GOIRC) study. J Immunother. 2010; 33: 735-741.
20. Jonasch E, Lal LS, Atkinson BJ, et al., Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int. 2011; 107: 741-747.
21. Roubaud G, Gross-Goupil M, Wallerand H, de Clermont H, Dilhuydy MS, Ravaud A,. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology. 2011; 80: 214-218.
22. Ku JH, Park YH, Myung JK, Moon KC, Kwak C, Kim HH,. Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation. Urol Oncol. 2011; 29: 731-737.
23. Dias-Santagata D, Akhavanfard S, David SS, et al., Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010; 2: 146-158.
24. Wagle N, Berger MF, Davis MJ, et al., High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012; 2: 82-93.
25. Pal SK, He M, Tong T, et al., RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res. 2015; 13: 130-137.
26. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499: 43-49.
27. Heng DY, Xie W, Regan MM, et al., Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.
28. Tang PA, Vickers MM, Heng DY,. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am. 2011; 25: 871-891.